Pharmacological effects of small molecule BCR-ABL tyrosine kinase inhibitors on platelet function
- 8 October 2024
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 392 (1) , 100020
Abstract
Tyrosine kinase inhibitors (TKIs) targeting the breakpoint cluster region-ABL fusion protein, such as imatinib (Gleevec), have revolutionized targeted cancer therapies. However, drug resistance and side effects, particularly those affecting hemostasis, continue to pose significant challenges for TKI therapies. As tyrosine kinases serve pivotal roles in platelet hemostatic function, we investigated the potential impact of both established and emerging ABL TKIs on human platelet activities ex vivo. Our study included standard-of-care agents (eg, imatinib and nilotinib) and second-generation ABL inhibitors, including ponatinib and bosutinib, designed to mitigate drug resistance. Additionally, we explored the effects of allosteric inhibitors targeting the myristoyl pocket of ABL (eg, asciminib and GNF-2) and novel agents in preclinical development, including ELVN-919, which uniquely exhibits high specificity for the ABL kinase active site. Our findings reveal that while ABL inhibitors such as ponatinib and bosutinib impede platelet activity, highly specific new-generation ABL inhibitors, including first-in-class therapeutics, do not impact platelet function ex vivo. Overall, these new insights around the effects of ABL TKIs on platelet function could inform the development of targeted therapies with reduced hematologic toxicities. SIGNIFICANCE STATEMENT: This study examines the effects of clinically relevant small molecule breakpoint cluster region (BCR)-ABL tyrosine kinase inhibitors (TKIs) on platelet activity. This analysis includes first-time assessments of agents such as asciminib and ELVN-919 on human platelet function ex vivo, alongside established therapies (eg, imatinib, ponatinib) with well characterized effects on platelet function, to discern potential antiplatelet and other effects of BCR-ABL TKIs and inform clinical safety.Keywords
Funding Information
- American Society of Hematology
- National Heart Lung and Blood Institute (R01HL144133, R01HL101972, R01HL146549, F30HL158079, R01HL151367)
- American Heart Association Inc (23IAUST1019750)
This publication has 42 references indexed in Scilit:
- Management of Chronic Myeloid Leukemia Patients in Later Lines: The Role of Ponatinib and New CompoundsClinical Lymphoma Myeloma and Leukemia, 2023
- A new function for MAP4K4 inhibitors during platelet aggregation and platelet-mediated clot retractionBiochemical Pharmacology, 2021
- Bosutinib reduces endothelial permeability and organ failure in a rat polytrauma transfusion modelBritish Journal of Anaesthesia, 2021
- Varying effects of tyrosine kinase inhibitors on platelet function—A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?Cancer Medicine, 2019
- Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutationCancer, 2017
- The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shearThrombosis Research, 2015
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- Platelet α-granules: Basic biology and clinical correlatesBlood Reviews, 2009
- Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606Leukemia Research, 2007
- Imatinib as a Paradigm of Targeted Therapies2004